Tara Cochrane
About
Tara Cochrane is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology.
According to data from OpenAlex, Tara Cochrane has authored 36 papers receiving a total of 156 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Genetics, 17 papers in Pathology and Forensic Medicine and 15 papers in Oncology. Recurrent topics in Tara Cochrane's work include Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Multiple Myeloma Research and Treatments (8 papers). Tara Cochrane is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Chronic Lymphocytic Leukemia Research (15 papers) and Multiple Myeloma Research and Treatments (8 papers). Tara Cochrane collaborates with scholars based in Australia, United States and United Kingdom. Tara Cochrane's co-authors include Bhadran Bose, Kylie Alcorn, Jing Sun, Peter Irwin, Amy V. Jennison, Nada Hamad, Eliza A. Hawkes, Rikki Graham, Amanda Barbosa and N Weber and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Clinical Infectious Diseases.
In The Last Decade
Tara Cochrane
32 papers receiving 153 citations
Peers
Tara Cochrane
Catherine Settegrana France
Ana Lisa Basquiera Argentina
Amrith Mathew India
Sylvain Pilorge France
O. V. Reshetko Russia
Maria Enza Mitra Italy
Anna Waszczuk‐Gajda Poland
Nadira Duraković Croatia
Keijiro Sato Japan
Citations per year, relative to Tara Cochrane Tara Cochrane (= 1×)
peers
Catherine Settegrana
Countries citing papers authored by Tara Cochrane
Since
Specialization
Citations
This map shows the geographic impact of Tara Cochrane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tara Cochrane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tara Cochrane more than expected).
Fields of papers citing papers by Tara Cochrane
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Tara Cochrane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tara Cochrane. The network helps show where Tara Cochrane may publish in the future.
Co-authorship network of co-authors of Tara Cochrane
This figure shows the co-authorship network connecting the top 25 collaborators of Tara Cochrane. A scholar is included among the top collaborators of Tara Cochrane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tara Cochrane. Tara Cochrane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dhakal, Binod, Hang Quach, Andrew Spencer, et al.. (2024). Dose Escalation of ISB 1442, a Novel CD38 Biparatopic x CD47 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma. Blood. 144(Supplement 1). 3364–3364.
2.
Churilov, Leonid, Andrew Grigg, Joel Wight, et al.. (2024). Infection risk and antimicrobial prophylaxis in bendamustine‐treated patients with indolent non‐Hodgkin lymphoma: An Australasian Lymphoma Alliance study. British Journal of Haematology. 205(1). 146–157.
3.
Verner, Emma, Amanda Johnston, Eliza A. Hawkes, et al.. (2024). Ibrutinib plus rituximab and mini-CHOP in older patients with newly diagnosed DLBCL: a phase 2 ALLG study. Blood Advances. 8(21). 5674–5682.
4.
Wellard, Cameron, Geoffrey Chong, Tara Cochrane, et al.. (2024). Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era. Internal Medicine Journal. 54(7). 1223–1227.
5.
Lewis, Katharine L., Pratyush Giri, Piers Blombery, et al.. (2024). Interim Safety Analysis of ALLG-Pacific (NHL35): An Open Label Phase II Study of Pembrolizumab and Chemo-Immunotherapy As First-Line Therapy for Primary Mediastinal B-Cell Lymphoma. Blood. 144(Supplement 1). 1721–1721.
6.
Polizzotto, Mark N., Sam Milliken, Tara Cochrane, et al.. (2023). Outcomes of human immunodeficiency virus‐associated Burkitt lymphoma and diffuse large B‐cell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance. British Journal of Haematology. 201(5). 865–873.
7.
Verner, Emma, Anna Johnston, Eliza A. Hawkes, et al.. (2023). Final analysis of Australasian Leukaemia & Lymphoma Group NHL29: A phase II study of ibrutinib, rituximab and mini‐CHOP in very elderly patients with newly diagnosed DLBCL. Hematological Oncology. 41(S2). 426–427.
8.
Trotman, Judith, Daniel Carradice, Maher K. Gandhi, et al.. (2023). Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study. HemaSphere. 7(3). e836–e836.
9.
Gill, Harinder, Francesca Palandri, David M. Ross, et al.. (2023). Bomedemstat (IMG-7289), an LSD1 Inhibitor, Manages the Signs and Symptoms of Essential Thrombocythemia (ET) While Reducing the Burden of Cells Homozygous for Driver Mutations. Blood. 142(Supplement 1). 747–747.
10.
Cochrane, Tara, Alicia Enrico, David Gómez‐Almaguer, et al.. (2021). Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. Leukemia & lymphoma. 63(2). 304–314.
11.
Verner, Emma, Amanda Johnston, Eliza A. Hawkes, et al.. (2021). Efficacy of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma: Primary Analysis of the Australasian Leukaemia & Lymphoma Group NHL29 Study. Blood. 138(Supplement 1). 304–304.
12.
Palandri, Francesca, Nicola Vianelli, David M. Ross, et al.. (2021). A Phase 2 Study of the LSD1 Inhibitor Img-7289 (bomedemstat) for the Treatment of Essential Thrombocythemia (ET). Blood. 138(Supplement 1). 386–386.
13.
Mollee, Peter, John Reynolds, Wojciech Janowski, et al.. (2021). A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood. 138(Supplement 1). 2728–2728.
14.
Alcorn, Kylie, Tara Cochrane, Rikki Graham, et al.. (2020). First Report of Candidatus Mycoplasma haemohominis Infection in Australia Causing Persistent Fever in an Animal Carer. Clinical Infectious Diseases. 72(4). 634–640.
15.
Tan, Xuan, et al.. (2020). Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance. Leukemia & lymphoma. 61(14). 3412–3416.
16.
Verner, Emma, Amanda Johnston, Eliza A. Hawkes, et al.. (2019). Response Rates and Quality of Life Outcomes in Australasian Leukaemia & Lymphoma Group NHL29: A Phase II Study of Ibrutinib, Rituximab and Mini-CHOP in Very Elderly Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma. Blood. 134(Supplement_1). 4094–4094.
17.
Cochrane, Tara, Tatiana Chagorova, Tadeusz Robak, et al.. (2018). Venetoclax Improves Quality of Life for Patients with Elapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 132(Supplement 1). 4858–4858.
18.
Bose, Bhadran, et al.. (2015). FP535ARTERIAL LINE VERSUS VENOUS LINE ADMINISTRATION OF LOW MOLECULAR WEIGHT HEPARIN, ENOXAPARIN FOR PREVENTION OF THROMBOSIS IN THE EXTRACORPOREAL BLOOD CIRCUIT OF PATIENTS ON HAEMODIALYSIS OR HAEMODIAFILTRATION - A RANDOMIZED CROSS-OVER TRIAL. Nephrology Dialysis Transplantation. 30(suppl_3). iii251–iii251.
19.
Keijzers, Gerben, et al.. (2013). Acute Stridor and Respiratory Failure due to Retrosternal Subglottic Stenosis of Unknown Origin. SHILAP Revista de lepidopterología. 2013. 1–4.
20.
Cochrane, Tara, et al.. (2007). Emergency management of upper airway angio-oedema after routine dental extraction in a patient with C1 esterase deficiency. British Journal of Oral and Maxillofacial Surgery. 46(5). 394–396.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Catherine Settegrana Breakdown of academic impact, for papers by Ana Lisa Basquiera Breakdown of academic impact, for papers by Amrith Mathew Breakdown of academic impact, for papers by Sylvain Pilorge Breakdown of academic impact, for papers by O. V. Reshetko Breakdown of academic impact, for papers by Maria Enza Mitra Breakdown of academic impact, for papers by Anna Waszczuk‐Gajda Breakdown of academic impact, for papers by Ram Vasudevan Nampoothiri Breakdown of academic impact, for papers by Nadira Duraković Breakdown of academic impact, for papers by Keijiro Sato